The goal of this study is to prospectively follow the level of circulating nucleosomes in patients treated for a non-Hodgkin lymphoma and determine whether it correlates with the clinical response.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
50
A maximum of 4 tubes of 10ml will be collected: at baseline (before cycle 1), before each cycle (from 2 to 6 included), at the end of the treatment, and in case of relapse during follow-up period
Gustave Roussy
Villejuif, France
RECRUITINGProspective quantitative analysis of the level of circulating nucleosomes at baseline and during treatment in patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL)
Time frame: From enrollment to the end of the study (24 months of follow-up from beginning of treatment for each patient)
Correlation between the level of circulating nucleosomes (number of cells) and the response to treatment as defined by international response criteria
We would like to understand whether the more nucleosomes circulating, the more the patient responds to treatment.
Time frame: From enrollment to the end of the treatment (6 cycles of 21 days)
Comparison between the results of molecular analysis of ctDNA and DNA extracted from nucleosomes
Time frame: From enrollment to the end of the study (24 months of follow-up from beginning of treatment for each patient)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.